TLDR:
- Xund, an Austrian health tech scale-up, has extended their seed round funding to €8M.
- The funding will be used to develop Medical Large Language Models (MedLLMs) to provide personalised medical content dynamically.
Vienna-based XUND, a health tech scale-up, announced on Tuesday that it has secured €2M in an extended Seed funding round, bringing the total funding raised to €8M. New investor Thieme Group participated in the funding round, along with existing investors, including MMC Ventures and MassMutual Ventures. Xund has been collaborating with Thieme Group since 2020 to improve patient communication by strengthening health literacy and patient confidence. The fund will help the Austrian company develop Medical Large Language Models (MedLLMs) to provide personalised medical content dynamically. Xund enables healthcare companies to digitise the patient journey and translate unstructured data into actionable insights. The company has developed four medical modules to cover the entire lifecycle of a patient and enable digital interactions from prevention to diagnosis and monitoring. Its flagship product is an AI-powered health assistant that provides symptom and risk assessment capabilities to help navigate patients to the best point of care. Xund’s technology is considered industry-leading and is used by leading insurance, pharmaceutical, and big tech companies. The investor MMC is a leading European venture capital firm with a focus on early-stage transformative technology companies. MassMutual Ventures (MMV) is a multistage global venture capital firm investing in financial technology, enterprise SaaS, healthtech, climate technology, and cybersecurity companies. Xund’s collaboration with Thieme Group and the support from investors will strengthen its position as an innovation leader in the healthcare industry.
